{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:23:01Z","timestamp":1791062581954,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The taxonomy of Kaposi Sarcoma (KS) is based on a classification system focused on the description of clinicopathological features of KS in geographically and clinically diverse populations. The classification includes classic, endemic, epidemic\/HIV associated and iatrogenic KS, and KS in men who have sex with men (MSM). We assessed the medical relevance of the current classification of KS and sought clinically useful improvements in KS taxonomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reviewed the demographic and clinicopathological features of 676 patients with KS, who were referred to the national centre for HIV oncology at Chelsea Westminster hospital between 2000 and 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Demographic differences between the different subtypes of KS exist as tautological findings of the current classification system. However, no definitive differences in clinicopathological, virological or immunological parameters at presentation could be demonstrated between the classic, endemic or MSM KS patients. Reclassifying patients as either immunosuppressed or non-immunosuppressed, showed that the immunosuppressed group had a significantly higher proportion of adverse disease features at presentation including visceral disease and extensive oral involvement, classified together as advanced disease (chi<jats:sup>2<\/jats:sup> P\u2009=\u20090.0012*) and disseminated skin involvement (chi<jats:sup>2<\/jats:sup> P\u2009&lt;\u20090.0001*). Immunosuppressed patients had lower CD4 counts, higher CD8 counts and a trend towards higher HHV8 levels compared to non-immunosuppressed patients, however overall survival and disease specific (KS) survival was similar across groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current system of KS classification does not reflect meaningful differences in clinicopathological presentation or disease pathogenesis. Reclassification of patients based on the presence or absence of immunosuppression is a more clinically meaningful system that may influence therapeutic approaches to KS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04130-6","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:01:42Z","timestamp":1682611302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-3067","authenticated-orcid":false,"given":"M. R.","family":"Openshaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gervasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. M.","family":"Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dalla Pria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"4130_CR1","unstructured":"Committee NRC. The National Academies Collection: A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press (US), National Academy of Sciences.; 2011."},{"issue":"2","key":"4130_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrd4537","volume":"14","author":"M Hofmann-Apitius","year":"2015","unstructured":"Hofmann-Apitius M, Alarc\u00f3n-Riquelme ME, Chamberlain C, McHale D. Towards the taxonomy of human disease. Nat Rev Drug Discov. 2015;14(2):75\u20136.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4130_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF01830024","volume":"4","author":"Kaposi","year":"1872","unstructured":"Kaposi. Idiopathisches multiples Pigmentsarkom der Haut. Archiv f\u00fcr Dermatologie und Syphilis. 1872;4(2):265\u201373.","journal-title":"Archiv f\u00fcr Dermatologie und Syphilis."},{"issue":"14","key":"4130_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJM200004063421407","volume":"342","author":"K Antman","year":"2000","unstructured":"Antman K, Chang Y. Kaposi\u2019s sarcoma. N Engl J Med. 2000;342(14):1027\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"6, Part 2","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0190-9622(90)70169-I","volume":"22","author":"AE Friedman-Kien","year":"1990","unstructured":"Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi\u2019s sarcoma. J Am Acad Dermatol. 1990;22(6, Part 2):1237\u201350.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/1097-0142(197208)30:2<553::AID-CNCR2820300236>3.0.CO;2-W","volume":"30","author":"JJ D'Oliveira","year":"1972","unstructured":"D\u2019Oliveira JJ, Torres FO. Kaposi\u2019s sarcoma in the Bantu of Mozambique. Cancer. 1972;30(2):553\u201361.","journal-title":"Cancer"},{"issue":"2","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00000372-198100320-00002","volume":"3","author":"GJ Gottlieb","year":"1981","unstructured":"Gottlieb GJ, Ragaz A, Vogel JV, Friedman-Kien A, Rywlin AM, Weiner EA, et al. A preliminary communication on extensively disseminated Kaposi\u2019s sarcoma in young homosexual men. Am J Dermatopathol. 1981;3(2):111\u20134.","journal-title":"Am J Dermatopathol"},{"issue":"13","key":"4130_CR9","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1056\/NEJMc070508","volume":"357","author":"T Maurer","year":"2007","unstructured":"Maurer T, Ponte M, Leslie K. HIV-associated Kaposi\u2019s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007;357(13):1352\u20133.","journal-title":"N Engl J Med"},{"issue":"2","key":"4130_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.7326\/0003-4819-75-2-310","volume":"75","author":"JL Fahey","year":"1971","unstructured":"Fahey JL. Cancer in the immunosuppressed patient. Ann Intern Med. 1971;75(2):310\u20132.","journal-title":"Ann Intern Med"},{"issue":"2","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1053\/j.seminoncol.2014.12.029","volume":"42","author":"AE Grulich","year":"2015","unstructured":"Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol. 2015;42(2):247\u201357.","journal-title":"Semin Oncol"},{"issue":"8","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jdv.14831","volume":"32","author":"D Denis","year":"2018","unstructured":"Denis D, Seta V, Regnier-Rosencher E, Kramkimel N, Chanal J, Avril MF, et al. A fifth subtype of Kaposi\u2019s sarcoma, classic Kaposi\u2019s sarcoma in men who have sex with men: a cohort study in Paris. J Eur Acad Dermatol Venereol. 2018;32(8):1377\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"4130_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00001648-199205000-00004","volume":"3","author":"CP Archibald","year":"1992","unstructured":"Archibald CP, Schechter MT, Le TN, Craib KJ, Montaner JS, O\u2019Shaughnessy MV. Evidence for a sexually transmitted cofactor for AIDS-related Kaposi\u2019s sarcoma in a cohort of homosexual men. Epidemiology. 1992;3(3):203\u20139.","journal-title":"Epidemiology"},{"issue":"5192","key":"4130_CR14","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science. 1994;266(5192):1865\u20139.","journal-title":"Science"},{"key":"4130_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","volume":"196","author":"D Ray","year":"2018","unstructured":"Ray D, Yung R. Immune senescence, epigenetics and autoimmunity. Clin Immunol. 2018;196:59\u201363.","journal-title":"Clin Immunol"},{"issue":"1","key":"4130_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1086\/509621","volume":"195","author":"C Casper","year":"2007","unstructured":"Casper C, Krantz E, Selke S, Kuntz SR, Wang J, Huang ML, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis. 2007;195(1):30\u20136.","journal-title":"J Infect Dis"},{"key":"4130_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-800098-4.00002-7","volume":"88","author":"L Giffin","year":"2014","unstructured":"Giffin L, Damania B. KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res. 2014;88:111\u201359.","journal-title":"Adv Virus Res"},{"key":"4130_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"4130_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","volume":"35","author":"R Peto","year":"1977","unstructured":"Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer. 1977;35:1\u201339.","journal-title":"Br J Cancer"},{"key":"4130_CR20","unstructured":"England PH. Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of December 2019. In: England PH, editor. 2019."},{"issue":"9","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/v10090458","volume":"10","author":"EM Etta","year":"2018","unstructured":"Etta EM, Alayande DP, Mavhandu-Ramarumo LG, Gachara G, Bessong PO. HHV-8 seroprevalence and genotype distribution in Africa, 198\u2013217: a systematic review. Viruses. 2018;10(9):458.","journal-title":"Viruses."},{"key":"4130_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1447-0594.2006.00341.x","volume":"6","author":"H Orimo","year":"2006","unstructured":"Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of \u201celderly.\u201d Geriatr Gerontol Int. 2006;6:149.","journal-title":"Geriatr Gerontol Int."},{"issue":"13","key":"4130_CR23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1097\/QAD.0b013e32832d080d","volume":"23","author":"M Bower","year":"2009","unstructured":"Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi\u2019s sarcoma. AIDS. 2009;23(13):1701\u20136.","journal-title":"AIDS"},{"issue":"24","key":"4130_CR24","first-page":"5868","volume":"21","author":"A Facciol\u00e0","year":"2017","unstructured":"Facciol\u00e0 A, Venanzi Rullo E, Ceccarelli M, D\u2019Aleo F, Di Rosa M, Pinzone MR, et al. Kaposi\u2019s sarcoma in HIV-infected patients in the era of new antiretrovirals. Eur Rev Med Pharmacol Sci. 2017;21(24):5868\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9534","key":"4130_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","volume":"368","author":"V Simon","year":"2006","unstructured":"Simon V, Ho DD, Abdool KQ. HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489\u2013504.","journal-title":"Lancet"},{"issue":"11","key":"4130_CR26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/QAD.0b013e3283601144","volume":"27","author":"P Unemori","year":"2013","unstructured":"Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, et al. Immunosenescence is associated with presence of Kaposi\u2019s sarcoma in antiretroviral treated HIV infection. AIDS. 2013;27(11):1735\u201342.","journal-title":"AIDS"},{"issue":"10","key":"4130_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2326-6066.CIR-18-0121","volume":"6","author":"N Galanina","year":"2018","unstructured":"Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Successful treatment of HIV-associated kaposi sarcoma with immune checkpoint blockade. Cancer Immunol Res. 2018;6(10):1129\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"4130_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1304337","volume":"6","author":"S Mletzko","year":"2017","unstructured":"Mletzko S, Pinato DJ, Robey RC, Dalla Pria A, Benson P, Imami N, et al. Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi\u2019s sarcoma: a pilot study. Oncoimmunology. 2017;6(8): e1304337.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04130-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:02:29Z","timestamp":1682611349000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04130-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04130-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"8 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Retrospective data collection was approved by the national centre for HIV malignancy. No Patient identifiable information was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not a case report and contains no patient identifiable information. All listed authors consent to publication of this final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra and Astra Zeneca; research funding (to institution) from MSD and BMS. Mark R Openshaw received travel expenses from Servier. No other conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}